Neuropsychiatric side effects of interferon-alfa therapy

Pharmacy World and Science

Volumn 25, Issue 1, 2003, Pages 11-20

  Van Gool, Arthur R ^a   Kruit, Wim H J ^a   Engels, Frederike K ^a   Stoter, Gerrit ^a   Bannink, Marjolein ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adverse drug reaction; Depression; Interferon; Neuropsychiatric; Side effect

Indexed keywords

ALPHA INTERFERON; CYTARABINE; PARACETAMOL; RIBAVIRIN;

ACADEMIC ACHIEVEMENT; ANEMIA; ANOREXIA; ARTHRALGIA; BEHAVIOR; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER PROGRAM; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INCIDENCE; INSOMNIA; IRRITABILITY; LETHARGY; LIBIDO DISORDER; MEDICAL INFORMATION; MEDICAL PRACTICE; MELANOMA; MENTAL DISEASE; MOOD DISORDER; MYALGIA; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTION; REVIEW; SUICIDAL BEHAVIOR; THOUGHT DISORDER; THYROID DISEASE;

BIOLOGICAL RESPONSE MODIFIERS; CLINICAL TRIALS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; MENTAL DISORDERS; SYNDROME;

EID: 0347296414     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022449613907     Document Type: Review

References (56)

1. Fauci AS, Braunwald E, Isselbacker KJ, Wilson JD, Martin JB, Kasper DL et al., editors. Harrisons' principles of internal medicine, 14th ed. New York: McGraw-Hill, 1998.
2. Vial T, Descotes J. Clinical toxicity of interferons. Drug Saf 1994; 10(2): 115-50.
3. Dusheiko G. Side effects of alpha interferon in hepatitis C. Hepatology 1997; 26(3 Suppl 1): 112S-21S.
4. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157(6): 867-76.
5. Kirkwood JM, Resnick GD, Cole BF. Efficacy, safety and risk-benefit analysis of adjuvant interferon alfa-2b adjuvant therapy in melanoma. Semin Oncol 1997; 24(1 Suppl 4): 16-23.
6. Donnelly S. Patient management strategies for interferon alfa-2b as adjuvant therapy of high-risk melanoma. Oncol Nurs Forum 1998; 25(5): 921-7.
7. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau J-L, Maloisel F et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997; 337(4): 223-9.
8. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321(22): 1501-6.
9. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B et al. Randomised trial of interferon alfa-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-10.
10. McHutchinson JG, Gordon SC, Schiff ER, Schiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavarin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339(21): 1485-92.
11. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alfa-2b alone or in combination with ribavarin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339(21): 1493-9.
12. Gaudin J-L, Faure P, Godinot H, Gerard F, Trepo C. The french experience of treatment of chronic type D hepatitis with a 12-months of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995; 15(1): 45-52.
13. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21(2): 241-3.
14. Fattovich G, Giustina G, Favaroto S, Ruol A, the Investigators of the Italian Liver Association. A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24(1): 38-47.
15. Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol 1998; 25(1)(Suppl 1): 9-13.
16. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000; 54(5): 565-72.
17. Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol 1988; 6(4): 355-9.
18. Rifflet H, Vuillemin E, Oberti F et al. Pulsions suicidaires chez des malades atteints d'hépatite chronique C au cours ou au décours du traitement par l'interféron alpha. Gastroenterol Clin Biol 1998; 22(3): 353-7.
19. Van Gool AR, Kruit WHJ, Cornelissen JJ, Berk L, Eggermont AMM, Bannink M. Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatr 1999; 11 (4): 120-4.
20. Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89(2): 356-62.
21. Lemonnier E, Condat B, Paillère-Martinot ML, Chollet R, Allilaire JF. Syndrome de persecution sous interféron: à propos d'un cas. Société Médico-Psychologique 1996; 154(4): 246-9.
22. Nozaki O, Takagi C, Takaoka K, Takata K, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci 1997; 51(4): 175-80.
23. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252(7): 938-41.
24. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis PJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology 1995; 45(5): 947-50.
25. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DR. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodefiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8(1): 74-81.
26. Capuron L, Ravaud A, Dantzer R. Timing and specifity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients. Psychosom Med 2001; 63(3): 376-86.
27. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Jones D, Rustgi V et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147(9): 1577-80.
28. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26(5): 596-600.
29. Hensley ML, Peterson BR, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000; 18(6): 1301-8.
30. McDonald, EM, Mann, AH, Thomas, HC. Interferons as mediators of psychiatric morbidity. Lancet 1987; 11(Nov 21): 1175-8.
31. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alfa treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42(12): 2482-6.
32. Malaguernera M, Di Fazio I, Restuccia S, Pistone G, Ferlito L, Rampello L. Interferon-alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon-alpha. Neuropsychobiology 1998; 37(2): 93-7.
33. Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M et al. Neurotoxicity of interferon-alfa in melanoma therapy. Cancer 1998; 83(3): 482-9.
34. Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12(5): 505-9.
35. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol 2000; 15(3): 300-3.
36. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha tretament for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96(1): 157-64.
37. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alfa can be used succesfully in patients with hepatitis C virus positive hepatitis who have a psychiatric illness. Eur J Gastroenterol Hepatol 1995; 7(2): 165-8.
38. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patients initial affective state. N Engl J Med 1999; 340(17): 1370.
39. Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M et al. Immunotherapy interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105(1-2): 45-55.
40. Miyoaka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156(7): 1120.
41. Pariante CM, Orrù MG, Baita M, et al. Treatment with interferon-alfa in patients with chronic hepatitis and mood and anxiety disorders. Lancet 1999; 354(July 10): 131-2.
42. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon-alfa. N Engl J Med 2001; 344(13): 961-6.
43. Kraus MR, Schäfer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon-alfa. N Engl J Med 2001; 345(5): 375-6.
44. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26(5): 643-52.
45. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety 1998; 7(4): 188-93.
46. Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18(11): 2316-26.
47. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa and depression. Hepatology 2000; 31(6): 1207-11.
48. Gleason OC, Yates WR. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 400: 510-2.
49. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13(6): 561-6.
50. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9(4): 273-7.
51. Konsman JP. Immune-to-brain communication. Academical thesis, University of Groningen, 2000.
52. Dantzer R, Aubert A, Bluthé R-M, Gheusi G, Cremona S, Layé S et al. Mechanisms of the behavioral effects of cytokines. In: Dantzer R, Wollman EE, Yirmiya R, editors. Cytokines, stress and depression. New York: Kluwer Academic / Plenum Publishers 1999.
53. Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. Psychol Med 2000; 30(2): 259-68.
54. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22(1): 86-90.
55. Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002; 7(5): 468-73.
56. Maes M, Smith R, Scharpé. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20(2): 111-6.